(II)

• Definition of optimal dose/dosing regimen

• Integration of:

  • animal data
  • early phase I PK data; population PK
  • simulation using MIC90s on bacterial species of the spectrum of clinical interest

• Proposed dosing regimen for clinical trials in phase 2 and 3.

Previous slide

Next slide

Back to first slide

View graphic version